Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Woodcock Says Patient Benefit Measures Are Biostatistics’ Next Frontier

Executive Summary

CDER director tells statisticians that trials have to be able to better answer patient benefit questions.

Advertisement

Related Content

FDA Sees Challenge In Distinguishing Lung Cancer Symptoms From Drug Side Effects
Biomarker Approvals At Pre-IND Stage Requested For Orphan Drugs
Should FDA Be Forced To Consider Development Time And Cost?
20 Is The Loneliest Number: FDA Disease Meeting Schedule Leaves Some Worried About Exclusion
Disease-Of-The-Quarter Club: FDA Plans 20 Patient Network Meetings Over Five Years
Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain

Topics

Advertisement
UsernamePublicRestriction

Register

PS055469

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel